Loading stock data…
Evaxion A/S (EVAX)
$3.20+0.11 (+3.56%)
Market ClosedLast close Jun 29
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evaxion A/S in the Healthcare sector is trading at $3.20 with a market capitalization of $30M. Wall Street consensus targets $11.25 (4 analysts), implying a +251.6% move over the next 12 months. The stock is currently near its 52-week low of $2.26, remaining 28.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +251.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $7.49M↑ | $37,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.82M↑ | -$4.05M↓ | $3.02M↑ | -$4.34M↓ | -$3.87M |
| Net Income | -$3.63M↑ | -$5.92M↓ | $4.62M↑ | -$4.83M↓ | -$1.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.19M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.30%
Volume
Today's trading volume
23,626
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts were trending higher late Monday
European Equities Traded in US as ADRs Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning with t
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
European equities traded in the US as American depositary receipts were trending higher late Friday
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Tuesday
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M